Life Science Investing Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44
Life Science Investing Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Life Science Investing Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Life Science Investing Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Life Science Investing Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Life Science Investing Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Life Science Investing Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
